|
East African Journal of Public Health
East African Public Health Association
ISSN: 0856-8960
Vol. 4, Num. 2, 2007, pp. 80-83
|
East African Journal of Public Heath, Vol. 4, No. 2, October
2007, pp. 80-83
APPRAISAL ON THE PREVALENCE OF MALARIA AND ANAEMIA
IN PREGNANCY AND FACTORS INFLUENCING UPTAKE OF INTERMITTENT PREVENTIVE
THERAPY WITH SULFADOXINE-PYRIMETHAMINE IN KIBAHA DISTRICT, TANZANIA.
1Donath S.Tarimo
1Department of Medical Parasitology & Entomology,
School of Public Health & Social Sciences, Muhimbili University of Health & Allied
Sciences, Dar es Salaam, Tanzania.
Correspondence to: Dr D.S.Tarimo, , P.O.Box 65217, Dar es Salaam,United
Republic of Tanzania. E-Mail:dtarimo@muchs.ac.tz
Received 15 January 2007, revised 10 May 2007; accepted for publication 20
May 2007
Code Number: lp07017
Abstract
Objective: To appraise the prevalence of malaria and anaemia
in antenatal mothers; and explore the factors influencing coverage of intermittent
preventive treatment (IPT) with sulfadoxine-pyrimethamine (SP) under operational
conditions in the national programme for malaria control in pregnancy.
Design: Descriptive cross-sectional survey.
Setting: The reproductive and child health clinic in Kibaha
district hospital, Tanzania
Subjects: Pregnant mothers on routine antenatal visits
Main outcome measures: Prevalence of malaria (peripheral
parasitaemia) and anaemia, coverage of IPT with SP and the factors influencing
coverage.
Results: A total of 395 mothers were recruited; 27.3% had
malaria. Moderate anaemia i.e. haemoglobin (Hb) level 8.0 - 10.9 g/dl was
detected in 56.7% of mothers; 34.2% had severe anaemia (Hb < 8.0 g/dl).
Hb > 8.0 g/dl was strongly associated with negative parasitaemia while
Hb < 8.0 g/dl was strongly associated with positive parasitaemia. About
a third (40.0%) of the mothers did not receive SP for IPT because of unavailability.
Of those receiving, about a third (40.0%) did not swallow the tablets at
the clinic because of empty stomach and sharing of water cups. Majority (90.1%)
were aware that SP was the drug for IPT and 77.2% held the perception that
IPT with SP has health benefits; however, 70.0% were not aware on the timing
for IPT.
Conclusion: Severe malarial anaemia is still a health problem
in pregnancy, conceivably due to low coverage of IPT with SP because of erratic
availability of SP. There is a major gap on appropriate timing for IPT with
SP that should be corrected.
Key words: Pregnancy, intermittent preventive therapy, malaria,
anaemia, Tanzania
Introduction
In malaria endemic areas of Africa, more than 20 million pregnant women are
at an increased risk of malaria morbidity and early neonatal and infant deaths
every year (1). In Tanzania, malaria is a major health problem in pregnancy,
thus in holoendemic areas, more than half (63.0%) of pregnant mothers contract
malaria (2). Malaria infection in pregnancy is associated with maternal
anaemia which, together with placental malaria lead to an increased risk of
intra-uterine growth retardation, abortion, pre-term delivery and low birth
weight, still births as well as mother-to-child HIV transmission (3). Currently,
in malaria endemic areas, SP is used for intermittent preventive treatment
(IPT) in the national programmes for malaria control in pregnancy. Two doses
of SP for IPT, 1st dose given in the 2nd trimester; 2nd dose
at the begging of the 3rd trimester would significantly decrease
the risks of maternal malaria to the foetus (4). Thus since August 2001, Tanzania
adopted the policy of SP for IPT in pregnancy, the 1st dose being
given in the 20th week of pregnancy and 2nd dose in between
the 30th and 36th week under a directly observed therapy
so as to improve coverage.
Although under research conditions IPT with SP was shown to be highly efficacious;
it is not known how effective this tool is under operational conditions. Despite
the very high rate (80.0%) of attendance to the Reproductive and Child Health
(RCH) clinics in Tanzania, only 29.0% of mothers would receive and take SP
for IPT (5); the picture being similar in other holoendemic settings (6). A
number of socio-cultural factors such as awareness of the benefits, availability & accessibility
at the RCH clinics, perceived efficacy & safety; and convenience for use
might influence receipt and uptake of SP for IPT (7).
Receipt and uptake of SP IPT may conceivably face barriers to acceptance because
often clients are worried about safety to the foetus and that in the absence
of symptoms they would see no reasons to take medicines (8). This is further
compounded by the widely held notion that SP is full of side effects especially
severe skin reactions that are associated with HIV / AIDS (9).
This study appraised the prevalence of malaria parasitaemia and anaemia in
pregnancy and explored the factors influencing receipt and uptake of SP IPT
for the control of malaria in pregnancy under the operational conditions of
the national malaria control programme.
Patients and methods
Study site and population sampling
The study was carried out at Tumbi Hospital, Kibaha district, along the coast
of Tanzania, that is holoendemic for malaria. The study population comprised
of antenatal mothers on their routine visits to the RCH clinic where mothers
get their routine antenatal care. Each mother is sent to the laboratory for
haemoglobin level and blood smear for malaria parasites, and would receive
treatment depending on findings; if parasitaemic would receive SP treatment
but however if not parasitaemic and is at the gestation age of 20 - 28 weeks
or 30 - 36 weeks she would receive SP for IPT. Consecutive consenting mothers
at exit points from the RCH clinic were invited to participate in the study.
The sample size was estimated based on a 50.0% prevalence of parasitaemia in
pregnant mothers that would give the maximum sample size using the formula
for cross-sectional surveys: N = (Z2 X P X q) / e2; where
Z is the standard normal deviate set at 1.96, P = 0.5, q = 0.5 and e (error
margin) = 0.05 that gives N = 385. In this study a sample of 395 antenatal
mothers were recruited.
Exit review of antenatal records & interview of mothers
At the exit point, consecutive consenting mothers provided their antenatal
visits books for review and they were interviewed on issues related to malaria
and anaemia control in pregnancy. The information extracted included: gravidity
and gestational age as well as findings of peripheral blood smear, haemoglobin
level and whether SP for IPT had been prescribed. Then using a semi-structured
questionnaire the socio-demographic characteristics (age, level of education,
marital status & occupation) of each mother were recorded; the interview
centred on awareness on the risks of malaria and anaemia in pregnancy and the
benefits of IPT with SP in pregnancy; motivations for use and non-use and the
perceived efficacy and safety of SP for IPT. The questionnaire included questions
such as: Do you think when you are pregnant you are especially at a high risk
of getting malaria and being anaemic? If you get malaria and anaemia
while pregnant, do you think your baby would be affected? Are you aware of
IPT with SP and the number of doses you should receive before delivery? Do
you think SP is efficacious and safe for use during pregnancy? Did you receive
and take SP for IPT in this visit and if not, why? The questions were translated
into Swahili and back to English; the final Swahili version was pre-tested
in the study population to ensure consistency and clarity to the respondents
Results
A total of 395 antenatal mothers were recruited; majority were married women
aged 18 - 34 years with a primary education (Table 1). Malaria parasites were
found in 27.3% mothers, 56.7% had moderate anaemia (Hb 8.0 - 10.9 g/dl) and
34.2% had severe anaemia (Hb < 8.0 g/dl) (Table 2). Having Hb > 8.0 g/dl
was highly significantly associated with negative parasitaemia, while Hb < 8.0
g/dl was highly significantly associated with positive parasitaemia. This indicates
that during pregnancy, moderate anaemia is contributed by factors other than
malaria such as nutritional deficiencies while severe anaemia is strongly contributed
by malaria (Table 3).
About a third (40.0%) of the mothers did not receive SP for IPT, the commonest
reason being unavailability of SP at visit (Table 4). Of those receiving SP
for IPT, there was the liberty to swallow the tablets under DOT at the clinic
or go to swallow the tablets at home. About a third (40.0%) of the mothers
receiving SP for IPT did not prefer to swallow the tablets at the clinic, main
reasons being dislike to take medicines on empty stomach and sharing of water
cups for swallowing medicines. The majority of the mothers (90.1%) were aware
that SP is the drug for IPT, however, more than half of the mothers were not
aware of the number of doses of SP IPT supposed to be received before term
(Table 5). More than two thirds (70.0%) of the mothers were not aware of the
timing for IPT with SP in accordance to the gestation age. Cumulatively, about
three quarters (77.2%) of the mothers held the perception that IPT with SP
has health benefits, implying that they would conceivably be willing to use
SP for IPT. However, of the mothers who perceived SP had health benefits, about
half of them mentioned benefits that were not directly related to SP while
only a fifth (20.0%) mentioned benefits directly related to SP in terms of
preventing malaria effects to the mother and the baby.
Discussion
Malaria in pregnancy is undoubtedly an important public health problem in
malaria endemic areas of Tanzania, which prompted the Ministry of Health to
introduce SP IPT for malaria control in pregnancy. This study appraised the
prevalence of malaria and anaemia in pregnancy and the factors influencing
receipt and uptake of SP for IPT at an antenatal clinic in a malaria holoendemic
area. The presence of peripheral parasitaemia in 27.3% of the antenatal
mothers indicates that there is the potential for placental malaria that would
conceivably affect the foetus (4). Although other factors such as nutritional
deficiencies contribute to maternal anaemia, the presence of peripheral parasitaemia
would certainly contribute to anaemia hence the reason for more than three
quarters of the mothers being anaemic with haemoglobin below 10.9 g/dL (3).
In particular, having severe anaemia (Hb < 8.0 g/dL) was strongly associated
with peripheral parasitaemia indicating that malaria was the most likely cause
of anaemia. Severe anaemia carry serious consequences to the mother and the
fetus (1) hence the need to scale up interventions for malaria control in pregnancy
such as use of SP for IPT and insecticide treated nets.
A number of reasons such as non-receipt of SP for IPT due to unavailability
at the clinic as well as other socio-cultural factors could explain why implementation
of IPT with SP is not optimal. Thus, though about two thirds of the pregnant
mothers received SP for IPT, about a third (40.0%) preferred to swallow the
medicines at home raising doubts about compliance. Dispensing drugs for subsequent
use at home may potentially lead to poor compliance hence the actual coverage
would only include the mothers who swallowed SP for IPT under DOT. Strategies
that would ensure mothers do not stay long in the RCH clinics till they are
hungry as well provision of disposal cups for swallowing medicines would improve
uptake of SP for IPT under DOT. The unavailability of SP as the reason
for non-receipt of SP for IPT indicates the need to improve procurement and
delivery of SP so as to ensure a constant availability during clinic visits. The
actual coverage of SP IPT is the proportion of pregnant mothers who received
and swallowed SP for IPT at the clinic that is only 40.0%, which is below the
Abuja target that envisaged a 60.0% coverage by the year 2005 (10).
Public health educational messages regarding use of SP for IPT in pregnancy
seems to have been very well received as the great majority (90.1%) were aware
that SP was the drug for IPT, and about 75.0% held the perception that use
of SP for IPT has health benefits though only 20.0% linked this with prevention
of malaria effects in the mother and the baby. The fact that 70.0% of the mothers
were not aware on the timing of SP for IPT indicates a major gap in public
health education regarding the appropriate gestation for taking SP for IPT.
Lack of awareness on the correct gestation for the timing of SP for IPT may
conceivably be related to late first booking and erratic attendance to antenatal
clinics (11).
Conclusion
Despite the introduction of SP for IPT in pregnancy, severe malarial anaemia
is still a major health problem among antenatal mothers in this area because
of low coverage. To ensure optimal coverage, there is the need to improve
stocking of SP tablets at the RCH clinics, sensitize mothers for early booking
and ensure every antenatal mother due for IPT swallows SP under DOT.
Acknowledgment
Special thanks go the antenatal mothers attending to the Reproductive & Child
Health Clinic at Tumbi Hospital, Kibaha for their acceptance and time devoted
for participation in the study. Thanks go to the staff of the Reproductive & Child
Health Clinic at Tumbi Hospital, Kibaha for their extended cooperation in this
study. Thanks are due to the authority of Tumbi Hospital for giving permission
to use the laboratory data from the antenatal mothers.
Table 1: Socio-demographic characteristics of the study population
(N = 395)
Attribute |
No (%)
|
Age group (years)
< 18
18 - 34
35 - 40
|
19 (4.8)
349 (88.4)
27 (6.8)
|
Gravidity
Primigravidae
Secundagravidae
Multigravidae
|
146 (37.0)
115 (29.0)
134 (34.0)
|
Gestation (weeks)
< 20
20 - 24
25 - 29
30 - 36+
|
44 (11.2)
147 (37.2)
98 (24.8)
106 (26.8)
|
Marital status
Married
Not married
Widowed, separated & co-habiting)
|
275 (69.8)
68 (17.2)
52 (13.0)
|
Educational level
No formal education
Primary
Secondary
|
52 (13.2)
278 (70.4)
65 (16.4)
|
Occupation
Peasant
Employed / petty business
Unemployed
|
165 (41.8)
90 (22.2)
142 (36.0)
|
Table 2: Laboratory characteristics of the study population
(N
= 395)
Attribute |
No (%)
|
Peripheral malaria parasitaemia
Positive
Negative
|
108 (27.3)
287 (72.7)
|
Haemoglobin
≥ 11.0 g/dl
8.1 - 10.9 g/dl
≤ 8.0 g/dl
|
32 (8.1)
224 (56.7)
135 (34.2)
|
Table 3: Association of haemoglobin level with malariaparasitaemia status (N
= 395)
Haemoglobin levels (g/dl)
|
Parasitaemia +ve
No (%)
|
Parasitaemia -ve
No (%)
|
P-value
|
> 8.0
|
40 (37.0)
|
220 (76.7)
|
0.001
|
< 8.0
|
68 (63.0)
|
67 (23.3)
|
0.001
|
Table 4: Distribution of antenatal mothers according to receipt and
uptake of SP for IPT in the current visit (N = 395)
Attribute |
N (%) |
Receipt of SP IPT (N = 395)
Received
Did not receive
|
250 (63.3)
145 (36.7)
|
Reasons for non-receipt (n = 145)
SP not give
Gestation < 20 weeks
History of reaction to SP
|
95 (65.5)
44 (30.3)
6 (4.2)
|
Uptake of SP IPT (n = 250)
Taken at clinic
Did not take at clinic
|
154 (61.6)
96 (38.4)
|
Reasons for not taking SP IPT at clinic
Sharing of cups
Not taken food (empty stomach)
|
41 (42.7)
55 (57.3)
|
Table 5: Awareness on issues related to SP for IPT in pregnancy (N
= 395)
Attribute |
No (%)
|
SP as the drug for IPT
Aware
Not aware
|
356 (90.1)
39 (9.9)
|
Number of SP IPT doses
One dose
Two doses
Not aware
|
80 (20.3)
93 (23.5)
222 (56.2)
|
Timing for SP IPT
5th to 7th month of pregnancy
8th to 9th month of pregnancy
Not aware
|
82 (20.6)
37 (9.4)
276 (70.0)
|
Perceived benefits of SP IPT
Prevents malaria effects in mother & baby
Benefits unrelated to SP use
Not sure
|
79 (20.0)
226 (57.2)
90 (22.8)
|
References
- Guyatt HL, Snow RW. Malaria in Pregnancy as an indirect cause of infant
mortality in sub-Saharan Africa. Trans R Trop Med Hyg 2001; 95: 569
- 576
- Lipyoga R. Association between malaria in pregnancy and placenta abruption
in Dar es Salaam, Tanzania. MMED Dissertation (Obs & Gyn), University
of Dar es Salaam; 1995.
- Steketee RW, Wirima JJ, Slutsker L, Khoromana CO, Heymann DL, Breman JG. Malaria
treatment and prevention in pregnancy: indications for use and adverse events
associated with use of chloroquine or mefloquine. Am J Trop Med Hyg 1996;
55(suppl.): S50-S56
- Shulman CE, Dorman EK, Cutts F et al., Intermittent sulfadoxine-pyrimethamine
to prevent severe anaemia secondary to malaria in pregnancy: a randomised
placebo-controlled trial. Lancet 1999; 353 (9153): 632-6
- Ministry of Health, Tanzania. National Malaria Medium Term Strategic Plan
2002 - 2007, Dar es Salaam, Tanzania 2002.
- Guyatt H.L, Noor A.M, Ochola S.A, Snow R.W. Use of intermittent presumptive
treatment and insecticide treated bed nets by pregnant women in four Kenyan
districts. Trop Med Int Health 2004; 9(2): 255 - 261
- Tarimo DS, Minjas JN, Bygbjerg IC (2001). Perceptions of chloroquine efficacy
and alternative treatments for uncomplicated malaria in a holoendemic area
of Tanzania: implications for the change of malaria treatment policy. Trop
Med & Int Health 2001; 6(12): 992 - 997
- Mnyika KS, Kabalimu TK, Lugoe WL. Perceptions and utilisation of malaria
prophylaxis among pregnant women in Dar es Salaam, Tanzania. East Afr
Med J. 1995; 72(7):431-5.
- Raviglione MC, Dinan WA, Pablos-Mendez A, Palagiano A, Sabatini MT (1988).
Fatal toxic epidermal necrolysis during prophylaxis with Pyrimethamine & Sulfadoxine
in a human immunodeficiency virus infected person. Arch Intern Med 1988;
148 (12): 2683 - 2685
- The Abuja declaration. Summit of Heads of States and Governments of African
Countries, Abuja, Nigeria, 2000.
- van Eijik AM, Ayisi JG, ter Kuile FO et al., Implementation of intermittent
preventive treatment with sulfadoxine-pyrimethamine for control
of malaria in pregnancy in Kisumu, western Kenya. Trop Med Int Health 2004;
9(5): 630 - 637.
© Copyright 2007 - East African Journal of Public Heath
|